Steady-State Pharmacokinetics of Once-Daily Cyclobenzaprine Extended Release: A Randomized, Double-Blind, 2-Period Crossover Study in Healthy Volunteers

Clinical Therapeutics

Volumn 33, Issue 6, 2011, Pages 746-753

  Darwish, Mona ^a   Hellriegel, Edward T ^a  

^a CEPHALON INC   (United States)

Author keywords

Cyclobenzaprine; Muscle spasm; Once daily; Pharmacokinetic profile; Skeletal muscle relaxant; Steady state

Indexed keywords

CYCLOBENZAPRINE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG RELEASE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY THROAT; FEMALE; FOLLOW UP; HALF LIFE TIME; HEADACHE; HUMAN; HUMAN EXPERIMENT; INFORMED CONSENT; MALE; MAXIMUM PLASMA CONCENTRATION; MULTIPLE CYCLE TREATMENT; NAUSEA; PATIENT SAFETY; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SOMNOLENCE; STEADY STATE; XEROSTOMIA;

ADULT; AMITRIPTYLINE; ANTIDEPRESSIVE AGENTS, TRICYCLIC; AREA UNDER CURVE; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HALF-LIFE; HUMANS; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 79959438275     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2011.05.045     Document Type: Article

References (17)

1. Borenstein D.G., Korn S. Efficacy of a low-dose regimen of cyclobenzaprine hydrochloride in acute skeletal muscle spasm: results of two placebo-controlled trials. Clin Ther 2003, 25:1056-1073.
2. Browning R., Jackson J.L., O'Malley P.G. Cyclobenzaprine and back pain: a meta-analysis. Arch Intern Med 2001, 161:1613-1620.
3. Nibbelink D.W., Strickland S.C., McLean L.F., et al. Cyclobenzaprine, diazepam and placebo in the treatment of skeletal muscle spasm of local origin. Clin Ther 1978, 1:409-424.
4. Katz W.A., Dube J. Cyclobenzaprine in the treatment of acute muscle spasm: review of a decade of clinical experience. Clin Ther 1988, 10:216-228.
5. Malanga G.A., Ruoff G.E., Weil A.J., et al. Cyclobenzaprine ER for muscle spasm associated with low back and neck pain: two randomized, double-blind, placebo-controlled studies of identical design. Curr Med Res Opin 2009, 25:1179-1196.
6. Winchell G.A., King J.D., Chavez-Eng C.M., et al. Cyclobenzaprine pharmacokinetics, including the effects of age, gender, and hepatic insufficiency. J Clin Pharmacol 2002, 42:61-69.
7. Nibbelink D.W., Strickland S.C. Cyclobenzaprine (Flexeril™): report of a postmarketing surveillance program. Curr Ther Res 1980, 28:894-903.
8. Darwish M., Hellriegel E.T., Xie F. Single-dose pharmacokinetics of once-daily cyclobenzaprine extended release 30 mg versus cyclobenzaprine immediate release 10 mg three times daily in healthy young adults: a randomized, open-label, two-period crossover, single-centre study. Clin Drug Investig 2008, 28:793-801.
9. Darwish M., Xie F. Comparison of the single-dose pharmacokinetics of once-daily cyclobenzaprine extended-release 30 mg and cyclobenzaprine immediate-release 10 mg three times daily in the elderly: a randomized, open-label, crossover study. Drugs Aging 2009, 26:95-101.
10. Darwish M., Chang S., Hellriegel E.T. A pharmacokinetic comparison of single doses of once-daily cyclobenzaprine extended-release 15 mg and 30 mg: a randomized, double-blind, two-period crossover study in healthy volunteers. Clin Ther 2009, 31:108-114.
11. Darwish M., Xie F. Effect of food on the pharmacokinetics of once-daily cyclobenzaprine extended-release 30 mg: a randomized, open-label, crossover, single-centre study. Clin Drug Investig 2009, 29:145-152.
12. Declaration of Helsinki: ethical principles for medical research involving human subjects World Medical Association, Accessed May 18, 2011. http://www.wma.net/en/30publications/10policies/b3/17c.pdf.
13. ICH Harmonised Tripartite Guideline: Guideline for Good Clinical Practice E6 (R1) International Conference on Harmonisation Working Group, International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use; June 10, 1996; Washington, DC, Accessed May 18, 2011. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6_R1/Step4/E6_R1__Guideline.pdf.
14. Fleiss J.L. Design and Analysis of Clinical Experiments 1986, 264-270. John Wiley & Sons, New York, NY.
15. Bolton S. Pharmaceutical Statistics: Practical and Clinical Applications 1997, Marcel Dekker, New York, NY. 3rd ed.
16. Weil A.J., Ruoff G.E., Nalamachu S., et al. Efficacy and tolerability of cyclobenzaprine extended release for acute muscle spasm: a pooled analysis. Postgrad Med 2010, 122:158-169.
17. Till A.E., Constanzer M.L., Demetriades J., et al. Evidence for route dependent biotransformation of cyclobenzaprine hydrochloride. Biopharm Drug Dispos 1982, 3:19-28.